[CAS NO. 865783-99-9] Briciclib
PRODUCTS SPECIFICATIONS [865783-99-9]
DESCRIPTION [865783-99-9]
Overview
| MDL | MFCD22665751 |
|---|---|
| Molecular Weight | 474.42 |
| Molecular Formula | C19H23O10PS |
| SMILES | O=S(CC1=CC(OP(O)(O)=O)=C(OC)C=C1)(/C=C/C2=C(OC)C=C(OC)C=C2OC)=O |
Summary
Briciclib (ON 014185) is a derivative of ON 013100, and has the potential in targeting eIF4E for solid cancers.
IC50 & Target
|
eIF4 |
In Vitro
Briciclib has the potential in targeting eIF4E. Briciclib shows inhibitory activity against the proliferation of mantle cell leukemia (EKO-1 and MINO), breast (MCF7 and MDA-MB-231), gastric (AGS), and esophageal (OE19, OE33, and FLO-1) cancer cell lines with GI 50 s of 9.8-12.2 nM, and with no toxicity on normal endothelial cells. Briciclib dose-dependently reduces the expression of cyclin D1 and c-Myc in breast and MCL cancer cell lines within 8 hours [1] .
MCE has not independently confirmed the accuracy of these methods. They are for reference only.
Clinical Trial
| NCT Number | Sponsor | Condition | Start Date | Phase |
|---|---|---|---|---|
| NCT02168725 | Onconova Therapeutics, Inc. |
Neoplasms|Advanced Solid Tumor
|
June 2014 | Phase 1 |
Appearance
Solid
Shipping
Room temperature in continental US; may vary elsewhere.
Storage
| Powder | -20°C | 3 years |
|---|---|---|
| 4°C | 2 years | |
| In solvent | -80°C | 6 months |
| -20°C | 1 month |
Solvent & Solubility
DMSO : ≥ 31 mg/mL ( 65.34 mM )
* "≥" means soluble, but saturation unknown.
Stock Solutions
| Concentration Solvent Mass | 1 mg | 5 mg | 10 mg |
|---|
| 1 mM | 2.1078 mL | 10.5392 mL | 21.0784 mL |
| 5 mM | 0.4216 mL | 2.1078 mL | 4.2157 mL |
| 10 mM | 0.2108 mL | 1.0539 mL | 2.1078 mL |
